The impact of baseline left ventricular ejection fraction on 30-day and 1-year mortality after transfemoral transcatheter aortic valve implantatio

• Conditions: I35.0; I50.1; Aortic (valve) stenosis; Left ventricular failure

• Registration Number: DRKS00013729
• Lead Sponsor: niversitätsklinikum EssenWestdeutesches Herz- und Gefäßzentrum, EssenKlinik für Kardiologie und Angiologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2017-07-31
• Study Start: 2018-04-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 624

Inclusion Criteria

All patients with native severe aortic stenosis (AS) who underwent transfemoral transcatheter aortic valve implantation (TF-TAVI) in West German Heart and Vascular Center, Essen, from January 2006 to July 2016.

Exclusion Criteria

(1) Severe aortic regurgitation, degenerated aortic bioprosthesis or bicuspid aortic valve as a primary indication for transfemoral transcatheter aortic valve implantation (TF-TAVI), (2) Baseline transthoracic echocardiography not performed in our center, (3) TF-TAVI abrted/not performed

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
All-cause mortality at 30-day and 1-year follow-up. Mortality status (yes/no) and date were obtained from medical records, telephone contact with patients, next kin or their family physicians. Patients were censored at time of death or completion of 1-year follow-up, whichever occurred first.

Secondary Outcome Measures

Name	Time	Method
Interaction between the impact of baseline left ventricular ejection fraction (LVEF) and low gradient aortic stenosis (LGAS) on 30-day and 1-year mortality after TF-TAVI. This interaction will be assessed with Kaplan Meier method and Cox regression analysis.